BAMM (BRAF Autophagy and MEK Inhibition in Melanoma): A Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine in Advanced BRAFV600-mutant Melanoma.
Janice M MehnertTara C MitchellAlexander C HuangTomas S AlemanBenjamin J KimLynn M SchuchterGerald P LinetteGiorgos C KarakousisSheryl MitnickLydia GilesMary CarberryNoelle FreyAndrew KossenkovRoman GroisbergLeonel F Hernandez-AyaGeorge AnsstasAnn W SilkSunandana ChandraJeffrey A SosmanPhyllis A GimottyRosemarie MickRavi K AmaravadiPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
HCQ + D+T was well tolerated and produced a high RR but did not meet criteria for success for the one-year PFS rate. There was a high proportion of patients with pretreated and elevated LDH, an increasingly common demographic in patients receiving targeted therapy. In this difficult-to-treat population, the RR and PFS were encouraging. A randomized trial of D+T + HCQ or placebo in patients with BRAFV600-mutant melanoma with elevated LDH and previous immunotherapy is being conducted.